Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 ...

The Law Offices of Frank R. Cruz announces an investigation of Beta Bionics, Inc. ("Beta Bionics" or the "Company") (NASDAQ: ...

The DJS Law Group announces that it is investigating claims on behalf of investors of Beta Bionics, Inc. ("Beta Bionics" or ...

The downgrade comes after the Irvine-based medical device company reported preliminary fourth quarter results.

Beta Bionics reported Q4 2025 sales growth, but analysts raised concerns about valuation and slower patient starts.

The projected fair value for Beta Bionics is US$20.69 based on 2 Stage Free Cash Flow to Equity. Current share price of US$17 ...

Shares of Beta Bionics fell after the maker of insulin-delivery systems shared preliminary data for new patient starts that were below expectations. The stock slipped 36%, to $20.5, on Friday. Over ...

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, ...